BPC-157 + TB-500

What is the Wolverine Stack?

The Wolverine Stack is a nickname used by peptide vendors, clinics, and online communities for a two-peptide combination intended for recovery research. It is not a pharmacopoeial name, regulatory designation, or single fixed formula.

The name may describe two separate vials on different schedules, a co-lyophilized 1:1 vial (5/5 or 10/10 mg), a 1:2 blend (5/10 mg), BPC-157 paired with full-length Tβ4, or a larger blend containing KPV or GHK-Cu. Those products are not interchangeable.

The nickname suggests exceptionally fast healing but does not describe a measured pharmacological property. The combination should be judged by direct comparative data, not marketing imagery.

Composition and chemical identity

BPC-157 is a 15-amino-acid synthetic peptide (H-GEPPPGKPADDAGLV-OH, ~1,419.5 Da). TB-500 most consistently refers to Ac-LKKTETQ, the seven-residue N-acetylated fragment of thymosin beta-4 residues 17–23 (~889.01 Da).

BPC-157 acetate and TB-500 acetate are distinct bulk drug substances. Gross acetate material should not automatically be treated as the same mass of free peptide without assay and counterion correction.

Identity checks before interpreting a label

A blended vial is analytically more complex than either component alone. One overall HPLC purity number cannot establish both identities, both potencies, the true ratio, or combination stability.

The dose record should state µg or mg BPC-157 free-peptide equivalent and µg or mg Ac-LKKTETQ free-peptide equivalent separately. “One milligram of Wolverine” is incomplete unless the ratio is known.

U.S. medicinal and compounding status

There is no U.S. prescribing label or established medicinal-product dosage for the fixed BPC-157 + TB-500 combination. FDA's 2026 reviews evaluated the individual bulk drug substances, not a Wolverine fixed-combination product.

In July 2026, FDA staff recommended against adding reviewed free-base and acetate forms to the Section 503A Bulks List; the Pharmacy Compounding Advisory Committee subsequently recommended inclusion. Committee votes are advisory and do not validate the combination, its ratio, or any dosing schedule.

No U.S. Wolverine prescribing dose exists. A compounded vial does not prove efficacy.

Has the exact BPC-157 + TB-500 combination been studied?

Biçer and colleagues (2026) performed the first direct controlled comparison of BPC-157, TB-500, and the combination in tendon repair. Thirty-two rats underwent Achilles transection and Kessler repair, then received vehicle, BPC-157 10 µg/kg/day, TB-500 60 µg/kg/day, or both for 30 days IP.

The combination did not show an additive advantage. TB-500 alone produced the clearest biomechanical and several histological findings. The combination's median maximum load was below both monotherapy medians.

Dosage used in human research

No controlled human trial with chemically verified BPC-157 plus Ac-LKKTETQ was identified. The only published human combination observation is a small retrospective knee-pain chart review: four recipients received BPC-157 2–4 mg plus “TB4” 3–6 mg by separate intra-articular injections in one encounter. The second peptide was not analytically defined as Ac-LKKTETQ.

The BPC-only group in the same chart review reported 11 responses among 12 patients, so the study provides no signal that adding the second peptide improved the result. Three of four combination responders is three people — not an efficacy rate.

Published Wolverine Stack research dosage

The 2026 rat Achilles study is the strongest direct combination evidence. Doses were weight-based and administered IP beginning postoperative day 1 for 30 consecutive days.

For a representative 330 g rat: BPC-157 ≈ 3.3 µg/day; TB-500 ≈ 19.8 µg/day; combination total ≈ 23.1 µg/day. These values must not be converted into human doses or changed from IP to SC.

The paper named supplier catalog numbers but did not publish intact mass, sequence, N-terminal state, or peptide-equivalent assay for TB-500. The 60 µg/kg dose was selected from broader full-length Tβ4 literature — researchers should independently define the test article before replication.

Commonly reported anecdotal Wolverine protocols

The schedules below document online practice patterns. They are not clinical dosing guidelines and do not reproduce the controlled rat experiment.

Why fixed blends create dosing conflicts

In a 1:1 blend, every 250 µg increase in BPC-157 automatically adds 250 µg TB-500. The common separate-vial protocol uses different frequencies and a substantially different weekly ratio.

Complete evidence-anchored research protocol

The following four-arm rat replication protocol is based on the 2026 Biçer study. It is a nonclinical animal design — not a human regimen. It requires institutional animal-care approval, veterinary oversight, and a qualified research facility.

Do not convert IP rat doses to human SC doses. Do not double missed doses.

Banner: This protocol replicates an exploratory rat experiment. It does not establish a human dose, route, recovery benefit, or synergy claim.

Wolverine reconstitution and U-100 syringe math

These tables show fixed-ratio concentration arithmetic only. They do not establish a dose or verify formulation quality. “Final volume” means measured total volume after reconstitution.

Draw volume (mL) = target component mass (mg) ÷ component concentration (mg/mL). U-100 units = volume (mL) × 100.

Reported Wolverine dosage range

Published research versus community dosing

Proposed mechanisms and the synergy question

BPC-157 has been linked in preclinical models to tendon-fibroblast migration, FAK-paxillin signaling, VEGFR2/Akt/eNOS pathways, and extracellular-matrix organization. Ac-LKKTETQ is studied in relation to cytoskeletal dynamics, migration, and metabolism — though direct parent-fragment activity is not uniform across models.

Synergy has not been demonstrated. The 2026 rat study tested the practical prediction at 10:60 µg/kg/day IP and found no additional combination benefit over monotherapy.

Common claims vs evidence

Dosage evidence ladder

Wolverine dosing is poorly established. The combination now has one direct controlled animal experiment, but it did not show superiority over monotherapy and cannot define a human regimen. Community schedules remain anecdotal.

Safety and monitoring

No exact-combination adverse-event rate is available. The 2026 rat study reported no deaths, infections, wound complications, or reruptures in 32 young healthy male rats over 30 days — but this cannot establish human systemic, reproductive, immune, cancer, or long-term safety.

Potential harm can arise from wrong identity, incorrect ratio, microbial contamination, aggregates, incompatible pH, degradation, and administration error. A blended vial makes it harder to identify which component caused a reaction.

Storage and stability

No published stability study was identified for a co-lyophilized BPC-157 + Ac-LKKTETQ blend across common reconstitution volumes and a multiweek use period. Community pages often specify refrigeration at 2–8°C and use within ~28 days — conventions, not combination-specific stability data.

If the two peptides are prepared in one solution, compatibility and stability must be demonstrated for the combination. Otherwise track each component independently.

Anti-doping status

BPC-157 is prohibited at all times under WADA's S0 category. The 2026 Prohibited List separately names thymosin-β4 and its derivatives, including TB-500, under S2.3. A Wolverine blend therefore contains two prohibited components and is incompatible with tested sport.

Bottom line

The Wolverine Stack is not one standardized product. A scientifically interpretable formulation must separately verify BPC-157 and Ac-LKKTETQ, their salt forms, peptide-equivalent amounts, ratio, impurities, and post-reconstitution stability.

The strongest direct combination evidence is the 2026 rat Achilles-repair study: BPC-157 10 µg/kg/day plus TB-500 60 µg/kg/day, IP once daily for 30 days — with no additive benefit over monotherapy. Community protocols use different identities, ratios, routes, and schedules and should be presented as anecdotal conventions, not clinical dosing.

Confirm Ac-LKKTETQ identity (not full-length Tβ4), vial ratio (1:1 vs 1:2), and whether the product is a blend or separate vials — before trusting any unit chart. This stack is ≠ GLOW/KLOW.

Frequently asked questions

References

• Biçer O et al.

  Effects of BPC-157 and TB-500 on Achilles tendon healing in rats

  2026 — first direct controlled combination study; no synergy.

• Lee E, Padgett B.

  Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain

  2021 — 4-person uncontrolled combo subgroup.

• FDA

  Scientific review of BPC-157 for 2026 PCAC

  Bulk drug substance review — not combination authorization.

• FDA

  Scientific review of TB-500 for 2026 PCAC

  Ac-LKKTETQ identity and chemistry.

• Esposito S et al.

  Identification of N-acetylated thymosin beta-4 17–23 in TB-500

  2012.

• Chang CH et al.

  BPC-157, tendon outgrowth, cell survival, and migration

  2011.

• WADA

  2026 Prohibited List

  BPC-157 (S0) and Tβ4 derivatives/TB-500 (S2.3) prohibited.